There are a number of considerations that can help streamline the pathway to the clinic. One of the first is which vector ...
Despite the undeniable ability of viral vectors to deliver genetic payloads, and despite the incredible promise of this approach to treat a vast variety of diseases—including metabolic, cardiovascular ...
The clinical application of self-inactivating (SIN) retroviral vectors has been hampered by the lack of reliable and efficient vector production technologies. To enable production of SIN γ-retroviral ...
As a lab within the Cooperative Center of Excellence in Hematology (CCEH) at Fred Hutch, the Vector Production core assists investigators with the design, construction, and/or production of viral ...
Therapeutic biologics are thriving, according to Zhou Jiang, director Cell Culture Services at Cytiva. “As we work to advance the next generation of therapeutics, we must address these challenges to ...
CDMOs are building cell and viral vector manufacturing facilities left and right, but Harvard says it just isn’t enough, at least to serve the Boston biotech hub. That is why a host of public and ...
Cell-free protein synthesis (CFPS) eliminates the need to maintain living cells and allows greater control of reaction conditions than in vivo expression systems but is limited by its sensitivity to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback